Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
PARP inhibitor delays disease progression when used after successful chemotherapy.
Two androgen receptor inhibitors improved survival by 33% in men with metastatic prostate cancer that responds to hormone therapy.
FDA approves Rozlytrek for cancers with certain gene mutations
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
The Affordable Care Act erases racial disparities in care for advanced cancers.
First KRAS targeted therapy shows promise for lung and colon cancer
NKTR-214 plus Opdivo has been granted an FDA breakthrough therapy designation for advanced melanoma.
Treatment involves selecting, multiplying and reinfusing cancer-fighting immune cells.
The results from an innovative, “virtual” clinical trial were presented at the 2019 ASCO Annual Meeting.
Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life.
“The bladder cancer research community pulled together to get this trial done,” says principal investigator Thomas Flaig, MD.
Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.
RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.
The test was able to identify many cancers, and their location, at early stages.
Researchers are continuing to identify potential biomarkers or specific clinical factors to identify the best candidates for treatments.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.